Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

22.7%

5 terminated/withdrawn out of 22 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

32%

7 trials in Phase 3/4

Results Transparency

60%

9 of 15 completed trials have results

Key Signals

1 recruiting9 with results

Enrollment Performance

Analytics

N/A

11(52.4%)

Phase 4

4(19.0%)

Phase 3

3(14.3%)

Phase 2

2(9.5%)

Phase 1

1(4.8%)

21Total

N/A(11)

Phase 4(4)

Phase 3(3)

Phase 2(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT06256575Not ApplicableRecruiting

Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis

Role: lead

NCT06382662Phase 4Completed

Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition

Role: lead

NCT06157177Phase 4Active Not Recruiting

Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.

Role: lead

NCT06348303Phase 4Completed

Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg

Role: lead

NCT05616962Not ApplicableCompleted

Vasculera in Participants With Lipedema

Role: lead

NCT04793711Not ApplicableTerminated

EpiCeram for Skin Protection in Healthcare Workers

Role: lead

NCT02361437Not ApplicableWithdrawn

Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers

Role: lead

NCT03179605Phase 2Terminated

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

Role: lead

NCT02749799Phase 4Completed

Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis

Role: lead

NCT02070965Phase 2Completed

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

Role: lead

NCT01967069Phase 3Completed

A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis

Role: lead

NCT02527421Phase 3Terminated

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

Role: lead

NCT01947491Phase 3Completed

A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis

Role: lead

NCT02936271Not ApplicableWithdrawn

Efficacy of Vasculera in Prevention on Post-op Pain and Edema Following Lower Extremity Venous Treatment in the Outpatient Setting

Role: collaborator

NCT00790985Not ApplicableCompleted

Efficacy of Flavocoxid 500 mg Compared With Naproxen 500 mg in Subjects With Moderate-severe Osteoarthritis of the Knee

Role: lead

NCT00928837Not ApplicableCompleted

Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee

Role: lead

NCT02683408Not ApplicableCompleted

Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon

Role: lead

NCT02582424Not ApplicableCompleted

Safety and Efficacy of PDL-0101 in Patients With Hyperlipidemias: a Pilot Study.

Role: lead

NCT00303017Not ApplicableCompleted

Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study

Role: lead

NCT00435292Not ApplicableCompleted

Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee

Role: lead